Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
August 25, 2009While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor. These findings by Christopher Li, M.D., Ph.D., and colleagues at Fred Hutchinson Cancer Research Center were published online Aug. 25 in the journal Cancer Research.
Hormonal therapy with drugs like tamoxifen is one of the most common treatments for breast cancer because it has been shown to reduce the risk of dying from the disease but, as this study suggests, it does have risks.
Comparing breast-cancer patients who received the estrogen-blocking drug tamoxifen to those who did not, the researchers found that while the drug was associated with a 60 percent reduction in estrogen receptor-positive, or ER positive, second breast cancer - the more common type, which is responsive to estrogen-blocking therapy - it also appeared to increase the risk of ER negative second cancer by 440 percent. "This is of concern, given the poorer prognosis of ER-negative tumors, which are also more difficult to treat," said Li, an associate member of the Hutchinson Center's Public Health Sciences Division.
These findings confirm preliminary research by Li and colleagues, published in 2001, which was the first to suggest a link between long-term tamoxifen use and an increased risk of ER-negative second cancers. "The earlier study had a number of limitations. For example, we did not have information on the duration of tamoxifen therapy the women received," Li said. "The current study is larger, is based on much more detailed data, and is the first study specifically designed to determine whether tamoxifen use among breast cancer survivors influences their risk of different types of second breast cancers," Li said.
This new study assessed history of tamoxifen use among 1,103 breast cancer survivors from the Seattle-Puget Sound region who were initially diagnosed with ER positive breast cancer between the ages of 40 and 79. Of these, 369 of the women went on to develop a second breast cancer. Nearly all of the women in the study who took adjuvant hormonal therapy used tamoxifen specifically. Detailed information about tamoxifen use was ascertained from telephone interviews and medical record reviews.
While the study confirmed a strong association between long-term tamoxifen therapy and an increased risk of ER-negative second cancer, it does not suggest that breast cancer survivors should stop taking hormone therapy to prevent a second cancer, Li said.
"It is clear that estrogen-blocking drugs like tamoxifen have important clinical benefits and have led to major improvements in breast cancer survival rates. However, these therapies have risks, and an increased risk of ER negative second cancer may be one of them. Still, the benefits of this therapy are well established and doctors should continue to recommend hormonal therapy for breast cancer patients who can benefit from it," Li said.
-
Tamoxifen chemoprevention tied to early detection of breast cancer
Oct 07, 2008 |
not rated yet |
0
-
Team discovers new inhibitors of estrogen-dependent breast cancer cells
Jun 16, 2008 |
not rated yet |
0
-
Herbal menopause therapy a good fit for breast cancer patients?
Oct 07, 2008 |
not rated yet |
0
-
Novel basis identified for tamoxifen failure
Dec 04, 2008 |
not rated yet |
0
-
Migraines associated with lower risk of breast cancer
Nov 06, 2008 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (33) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (5) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (2) |
0
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
-
Nutrition label stuffs and diets
Feb 02, 2012
- More from Physics Forums - Medical Sciences
More news stories
Researchers make breakthrough in stem cell research
(Medical Xpress) -- University of Queensland scientists have developed a world-first method for producing adult stem cells that will substantially impact patients who have a range of serious diseases.
50 minutes ago |
5 / 5 (2) |
0
|
Georgia Tech develops software for the rapid analysis of foodborne pathogens
2011 brought two of the deadliest bacterial outbreaks the world has seen during the last 25 years. The two epidemics accounted for more than 4,200 cases of infectious disease and 80 deaths. Software developed at Georgia Tech ...
42 minutes ago |
not rated yet |
0
Can Viagra treat childhood lymphatic disorder?
(Medical Xpress) -- A surprising potential therapy for severe, hard-to-treat malformations of the lymphatic system is now being studied at the Stanford School of Medicine and Lucile Packard Childrens Hospital: researchers ...
17 minutes ago |
not rated yet |
0
|
Don't ignore kids' snores
(Medical Xpress) -- Your ears arent playing tricks on you that is the sound of snoring you hear from the bedroom of your preschooler. Snoring is common in children, but in some cases it can be a symptom of a ...
7 minutes ago |
not rated yet |
0
WHO calls for stepped-up fight against leprosy
The World Health Organization called Monday for greater efforts to fight leprosy, warning the disfiguring disease was defying efforts to wipe it out across many countries in the Asia-Pacific region.
13 minutes ago |
not rated yet |
0
New molecule has potential to help treat genetic diseases and HIV
(PhysOrg.com) -- Chemists at The University of Texas at Austin have created a molecule that's so good at tangling itself inside the double helix of a DNA sequence that it can stay there for up to 16 days before ...
With climate change, today's '100-year floods' may happen every three to 20 years: research
Last August, Hurricane Irene spun through the Caribbean and parts of the eastern United States, leaving widespread wreckage in its wake. The Category 3 storm whipped up water levels, generating storm surges ...
Researchers make better heat sensor based on butterfly wings
(PhysOrg.com) -- Scientists have long known that butterfly wings produce their iridescent colors by bouncing light around and between tiny ridges in structures made of chitin. More recently they’ve discovered ...
Social psychologist: Lust makes you smarter and evidence that seven deadly sins are good for you
(Medical Xpress) -- Good news for lovers on Valentine’s Day - the seven deadly sins, including Lust, are good for you. University of Melbourne social psychologist Dr Simon Laham uses modern research to make a compelling ...
The joy of cheques
An electronic cheque which eliminates the need for costly processing by banks but preserves the simplicity and ease of a traditional cheque book has been designed by a team of academics in the UK.
Research shows promise in converting camelina oil into jet fuel
(PhysOrg.com) -- Researchers at Montana State University-Northern have developed a process to convert camelina oil to jet fuel and other high-value chemicals. MSU has applied for a U.S. patent and research is ongoing.